Industry
Biotechnology
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Loading...
Open
2.81
Mkt cap
48M
Volume
21K
High
2.91
P/E Ratio
-0.67
52-wk high
4.34
Low
2.73
Div yield
N/A
52-wk low
2.29
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 8:50 pm
Portfolio Pulse from Benzinga Insights
May 16, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 11:28 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 6:40 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 2:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.